Maxime Verhoeven

147 Cost-effectiveness of treat-to-target strategies over 5 years Supplementary Table 1 (continued) Hospital day, rehabilitation center per day 460 Hospital day, nursing home per day 168 Hospital day, intensive care per day 1600.5 Specialist per visit 97.25 Specialist in training per visit 121.5 Psychotherapist per visit 94 General practitioner per visit 66 Social worker per visit 65 Paramedical care per visit 35 Indirect non healthcare costs Variable Frequency costs Care at home per hour 50 Home help per hour 23 1 Additinoal costs for day admission, 2 Additional costs for day admission and co-medication, 3 if intra articular + €9.92 and if intra muscular + €2.75 Supplementary Table 2 Baseline characteristics of U-Act-Early patients (not) included in the post-trial follow-up. TCZ+MTX (n=75) TCZ (n=79) MTX (n=72) P-value Included in follow- up n=226 Not included in follow- up n=91 P-value Employed, n (%) 60 (80) 60 (76) 56 (78) 0.83 176 (78) 75 (82) 0.37 Working hours per week, mean (SD) 23.3 (15.2) 21.1 (16.0) 22.6 (16.8) 0.49 22.3 (16.0) 26.7 (13.9) 0.03 Female, n (%) 47 (63) 61 (77) 48 (67) 0.13 156 (69) 56 (62) 0.20 RF +, n (%) 53 (71) 55 (71) 58 (82) 0.21 166 (74) 63 (69) 0.38 Anti CCP +, n (%) 51 (68) 54 (69) 56 (79) 0.28 161 (74) 62 (68) 0.51 RF- and/or anti- CCP+, n (%) 55 (73) 62 (79) 64 (89) 0.06 181 (80) 68 (75) 0.26 Age (years), mean (SD) 53.8 (11.2) 55.5 (11.6) 53.7 (12.9) 0.63 54.3 (11.9) 51.1 (14.8) 0.09 Symptom duration (days), median (IQR) 27 (18-43) 25 (19-43) 28 (16-46) 0.96 26 (18-43) 27 (16-46) 0.83 DAS28, mean (SD) 5.1 (1.1) 5.3 (1.1) 5.0 (1.2) 0.33 5.2 (1.1) 5.4 (1.1) 0.25 HAQ, median (IQR) 1.3 (0.6-1.6) 1.3 (0.9-1.8) 1.0 (0.5-1.4) 0.17 1.1 (0.6-1.6) 1.1 (0.8-1.5) 0.98 TCZ+MTX= initial tocilizumab + methotrexate strategy group; TCZ= initial tocilizumab + placebo- methotrexate strategy group; MTX= initial methotrexate + placebo-tocilizumab strategy group; RF= rheumatoid factor, += positive; anti-CCP= anti-cyclic citrullinated peptide antibodies; SD= standard deviation; IQR= interquartile range; DAS28= disease activity score assessing 28 joints; HAQ= health assessment questionnaire score. 7